Welcome to our dedicated page for AETHLON MEDICAL news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on AETHLON MEDICAL stock.
Aethlon Medical Inc. (Nasdaq: AEMD) is an innovative medical technology company dedicated to addressing unmet medical needs in health and biodefense. The company's core focus is on developing the Hemopurifier®, a clinical-stage therapeutic device designed to combat cancer and life-threatening viral infections, and for use in organ transplantation. Aethlon’s proprietary technology, the Aethlon ADAPT™ platform, provides the foundation for a new class of therapeutics that target the selective removal of disease-enabling particles from the entire circulatory system.
The Hemopurifier®, designated as a breakthrough device by the FDA, has demonstrated broad-spectrum capabilities against exosomes that contribute to the progression of cancer and viruses like HIV and Hepatitis C. Recent developments include ongoing research and clinical trials to evaluate the device's safety and efficacy in removing harmful exosomes and viruses from blood. These trials are taking place in India and Australia, targeting patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.
Financially, Aethlon Medical reported a cash balance of approximately $8.0 million as of the end of 2023. The company also announced a public offering expected to raise around $4.7 million to support its clinical trials, research, and other corporate needs. The company's leadership, including Interim CEO and CFO Jim Frakes, is committed to advancing the Hemopurifier® and exploring new applications in oncology and infectious diseases.
Partnerships are a crucial aspect of Aethlon’s strategy. The company recently entered into a Materials Transfer Agreement with Santersus AG to explore potential synergies between the Hemopurifier® and Santersus' NucleoCapture devices for the treatment of cancer and organ transplantation. This collaboration aims to enhance the effectiveness of both technologies by combining their capabilities to remove specific harmful agents from the blood.
Overall, Aethlon Medical Inc. is at the forefront of developing groundbreaking medical devices aimed at improving outcomes for patients with severe health conditions, making significant strides in the fields of cancer and infectious diseases.
For more information, visit Aethlon Medical.
Aethlon Medical (NASDAQ: AEMD) reported key developments in its fiscal Q2 2024, including the enrollment of two patients in its Australian clinical trial for the Hemopurifier® device. The trial focuses on treating solid tumor patients who haven't responded to anti-PD-1 therapies. The company has expanded its trial sites, with Pindara Private Hospital now approved for enrollment and a third Australian hospital in the approval process. Additionally, Medanta Medicity Hospital in India received ethics committee approval for a similar trial. The company has implemented cost-cutting measures while maintaining focus on its oncology trials. This comes amid projections showing the solid tumors market is expected to reach $375.4 Billion by 2034.
Aethlon Medical (AEMD) reported fiscal Q2 2024 results and key developments. The company achieved enrollment of first two patients in its Hemopurifier® cancer trial at Royal Adelaide Hospital, Australia. A second site, Pindara Private Hospital, is now open for enrollment. The company received ethics committee approval from Medanta Medicity Hospital in India for a similar trial. Financial highlights include cash balance of $6.9 million and reduced operating expenses to $2.9 million, down 9% year-over-year. Net loss decreased to $2.8 million from $3.0 million in the prior year period. The company implemented cost-cutting measures and appointed James Frakes as permanent CEO.
Aethlon Medical (NASDAQ: AEMD) announced enrollment of its first patient in an Australian clinical trial for the Hemopurifier®, a device designed to combat cancer and viral infections. The trial focuses on patients with solid tumors showing stable or progressive disease during anti-PD-1 therapy. The first patient, enrolled on October 29, 2024, at Royal Adelaide Hospital, will undergo a two-month run-in period receiving anti-PD-1 therapy before potential Hemopurifier treatment. The trial aims to improve upon current 30-40% response rates to anti-PD-1 therapies by removing tumor-produced EVs from the bloodstream. The study will involve 9-18 patients and evaluate safety, feasibility, and optimal treatment intervals.
Aethlon Medical (AEMD) has enrolled the first patient in its Australian clinical trial of the Hemopurifier® at Royal Adelaide Hospital. The trial aims to evaluate safety, feasibility, and dosing in patients with solid tumors who haven't responded to anti-PD-1 therapies like Keytruda® or Opdivo®. The enrolled patient began a two-month run-in period on October 29, 2024, receiving anti-PD-1 therapy.
The trial will include 9-18 patients, focusing on the Hemopurifier's ability to remove tumor-produced Extracellular vesicles (EVs) from bloodstream. Currently, only about 30% of patients respond to anti-PD-1 therapies, and the company hopes to improve these response rates through their treatment.
Aethlon Medical (Nasdaq: AEMD), a medical therapeutic company developing products for cancer and infectious diseases treatment, announced it will release its fiscal second quarter financial results for the period ended September 30, 2024, on November 13, 2024 at 4:15 p.m. ET. The company will host a conference call at 4:30 p.m. ET the same day, featuring management's remarks and a Q&A session. Participants can register online or dial in directly, with replay available until December 13, 2024.
Aethlon Medical (Nasdaq: AEMD), a company developing products for cancer and infectious disease treatment, announced its participation in the 2024 Maxim Healthcare Virtual Summit. James Frakes, CEO and CFO, will engage in a fireside chat on October 15, 2024, at 4:30 pm ET.
The event, hosted by Anthony Vendetti, executive managing director and head of research at Maxim Group, offers an opportunity for investors to gain insights into Aethlon Medical's developments and strategies. Interested parties can access the company presentation by registering for the conference through the provided link.
Investorideas.com releases the second part of a series on immunotherapy for cancer treatment, featuring Aethlon Medical, Inc. (NASDAQ: AEMD). Key points include:
1. Immunotherapy shows promise in improving long-term survival for advanced melanoma patients.
2. Aethlon's Hemopurifier® aims to enhance anti-PD-1 therapy responses by removing tumor-produced extracellular vesicles.
3. Aethlon received ethics approval for a clinical trial in India, following approvals in Australia.
4. The trial will evaluate Hemopurifier® in solid tumor patients with stable or progressive disease during anti-PD-1 monotherapy.
5. Other companies like Immuneering and Iovance Biotherapeutics are also advancing immunotherapy treatments with promising results.
Aethlon Medical (Nasdaq: AEMD) has received full ethics approval from the Medanta Institutional Ethics Committee (MIEC) for its Hemopurifier® cancer trial in India. The trial, focusing on safety, feasibility, and dose-finding, will involve cancer patients with solid tumors not responding to anti-PD-1 antibodies like Keytruda® or Opdivo®. The study, to be conducted at Medanta Medicity Hospital, aims to evaluate the Hemopurifier as a treatment option for multiple tumor types.
The Hemopurifier is designed to remove tumor-produced extracellular vesicles (EVs) from the bloodstream, potentially improving response rates to anti-PD-1 therapies. The trial will involve 9-18 patients and monitor safety, adverse events, and changes in EV concentrations. Results are expected to inform future oncology efficacy trials and contribute to a subsequent Premarket Approval study.
Aethlon Medical (Nasdaq: AEMD), a company developing products for cancer and infectious diseases, has announced its participation in two virtual investor conferences in September 2024. The events are:
1. Life Sciences Investor Forum (Sept 19-20): James Frakes (Interim CEO/CFO) and Dr. Steven LaRosa (CMO) will present on Sept 19 at 1:30 pm ET. One-on-one meetings available.
2. Virtual Emerging Growth Conference (Sept 25): Presentation at 12:35 pm ET, followed by Q&A.
Both events offer live interaction, pre-registration, and archived webcasts. These conferences provide opportunities for investors to learn about Aethlon Medical's developments and engage with management directly.
The solid tumors market is expected to reach $375.4 Billion by 2034, with a CAGR of 7.45% from 2024-2034. Aethlon Medical (NASDAQ: AEMD) has activated a clinical trial site at Royal Adelaide Hospital for its Hemopurifier device in patients with solid tumors resistant to anti-PD-1 therapies. The trial aims to assess safety, feasibility, and dosing, with potential to improve response rates to immunotherapies by removing tumor-produced extracellular vesicles.
Other developments in the solid tumor space include Immuneering's positive initial data for IMM-1-104 in pancreatic cancer, and FDA approvals for new immunotherapy combinations from AstraZeneca, Merck, and GlaxoSmithKline for endometrial cancer. Roche's trastuzumab deruxtecan received accelerated approval for HER2-positive solid tumors across multiple cancer types.
FAQ
What is the current stock price of AETHLON MEDICAL (AEMD)?
What is the market cap of AETHLON MEDICAL (AEMD)?
What is Aethlon Medical Inc.?
What is the Hemopurifier®?
What are the recent developments for Aethlon Medical?
Who is leading Aethlon Medical?
What are exosomes and why are they important?
How is Aethlon Medical funded?
What collaborations does Aethlon Medical have?
What makes the Hemopurifier® unique?
Where can I find more information about Aethlon Medical?
What are the financial highlights of Aethlon Medical?
